Dr. Baker on Approaching Palliative Care for Children With Cancer

Video

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses approaching palliative care for children with cancer.

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses approaching palliative care for children with cancer.

Palliative care for children with cancer is inherently multidisciplinary, says Baker. A holistic approach must be taken with palliative or end-of-life care, which requires an entire team. This team will address issues related to suffering. Baker says that suffering is the antithesis of palliative care, just as the enemy of oncology is cancer. A child with cancer not only goes through physical symptoms, but psychosocial distress, spiritual and existential distress, and psychological distress.

A team approach looks all at angles of end-of-life care, which includes being there for the family of the child. Addressing the needs of the child, as well as the family who must re-enter the community, are ways that a team-based palliative care approach should operate, Baker says. This is a very complex part of cancer care, and cannot be done by 1 individual, making a team-based multidisciplinary approach imperative.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD